Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk CEO Lars Fruergaard Jorgensen has called attention to the complexities of the U.S. healthcare system while ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

Semaglutide — the active ingredient in Ozempic®, Wegovy®, and Rybelsus® — can reduce your appetite and curb food cravings to ...

"Their effects on vaginal health are an important consideration that is often overlooked," gynecologist Melanie Bone told Newsweek.

A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Health-care costs are going up and and yet, workers may still not get the coverage they want — particularly when it comes to drugs like Ozempic.